PDF Brochure - Research and Markets
PDF Brochure - Research and Markets
PDF Brochure - Research and Markets
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Brochure</strong><br />
More information from http://www.research<strong>and</strong>markets.com/reports/1574035/<br />
Acute Myelocytic Leukemia (AML) - Pipeline Review, Q1 2011<br />
Description: Acute Myelocytic Leukemia (AML) - Pipeline Review, Q1 2011<br />
Contents:<br />
Summary<br />
Global <strong>Markets</strong> Direct’s, 'Acute Myelocytic Leukemia (AML) - Pipeline Review, Q1 2011', provides an<br />
overview of the Acute Myelocytic Leukemia therapeutic pipeline. This report provides information on<br />
the therapeutic development for Acute Myelocytic Leukemia, complete with latest updates, <strong>and</strong><br />
special features on late-stage <strong>and</strong> discontinued projects. It also reviews key players involved in the<br />
therapeutic development for Acute Myelocytic Leukemia. 'Acute Myelocytic Leukemia (AML) -<br />
Pipeline Review, Q1 2011' is built using data <strong>and</strong> information sourced from Global <strong>Markets</strong> Direct’s<br />
proprietary databases, Company/University websites, SEC filings, investor presentations <strong>and</strong><br />
featured press releases from company/university sites <strong>and</strong> industry-specific third party sources, put<br />
together by Global <strong>Markets</strong> Direct’s team.<br />
Note-: Certain sections in the report may be removed or altered based on the availability <strong>and</strong><br />
relevance of data for the indicated disease.<br />
Scope<br />
- A snapshot of the global therapeutic scenario for Acute Myelocytic Leukemia.<br />
- A review of the Acute Myelocytic Leukemia products under development by companies <strong>and</strong><br />
universities/research institutes based on information derived from company <strong>and</strong> industry-specific<br />
sources.<br />
- Coverage of products based on various stages of development ranging from discovery till<br />
registration stages.<br />
- A feature on pipeline projects on the basis of monotherapy <strong>and</strong> combined therapeutics.<br />
- Coverage of the Acute Myelocytic Leukemia pipeline on the basis of therapeutic class, route of<br />
administration <strong>and</strong> molecule type.<br />
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of<br />
action <strong>and</strong> research & development progress.<br />
- Key discontinued pipeline projects.<br />
- Latest news <strong>and</strong> deals relating to the products.<br />
Reasons to buy<br />
- Identify <strong>and</strong> underst<strong>and</strong> important <strong>and</strong> diverse types of therapeutics under development for Acute<br />
Myelocytic Leukemia.<br />
- Identify emerging players with potentially strong product portfolio <strong>and</strong> design effective counterstrategies<br />
to gain competitive advantage.<br />
- Plan mergers <strong>and</strong> acquisitions effectively by identifying players with the most promising pipeline.<br />
- Devise corrective measures for pipeline projects by underst<strong>and</strong>ing Acute Myelocytic Leukemia<br />
pipeline depth <strong>and</strong> focus of Acute Myelocytic Leukemia therapeutics.<br />
- Develop <strong>and</strong> design in-licensing <strong>and</strong> out-licensing strategies by identifying prospective partners<br />
with the most attractive projects to enhance <strong>and</strong> exp<strong>and</strong> business potential <strong>and</strong> scope.<br />
- Modify the therapeutic portfolio by identifying discontinued projects <strong>and</strong> underst<strong>and</strong>ing the factors<br />
that drove them from pipeline.<br />
List of Tables<br />
List of Figures<br />
Introduction<br />
Global <strong>Markets</strong> Direct Report Coverage<br />
Acute Myelocytic Leukemia (AML) Overview
Therapeutics Development<br />
An Overview of Pipeline Products for Acute Myelocytic Leukemia (AML)<br />
Acute Myelocytic Leukemia (AML) Therapeutics under Development by Companies<br />
Acute Myelocytic Leukemia (AML) Therapeutics under Investigation by Universities/Institutes<br />
Late Stage Products<br />
Comparative Analysis<br />
Mid Clinical Stage Products<br />
Comparative Analysis<br />
Early Clinical Stage Products<br />
Comparative Analysis<br />
Discovery <strong>and</strong> Pre-Clinical Stage Products<br />
Comparative Analysis<br />
Companies Involved in Acute Myelocytic Leukemia (AML) Therapeutics Development<br />
Bristol-Myers Squibb Company<br />
Genzyme Corporation<br />
Johnson & Johnson<br />
Boehringer Ingelheim GmbH<br />
F. Hoffmann-La Roche Ltd.<br />
Sanofi-Aventis<br />
AstraZeneca PLC<br />
Eli Lilly <strong>and</strong> Company<br />
Seattle Genetics, Inc.<br />
medac GmbH<br />
Merck & Co., Inc.<br />
Micromet, Inc.<br />
Generex Biotechnology Corporation<br />
Takeda Pharmaceutical Company Limited<br />
Bio-Path Holdings, Inc.<br />
BioSante Pharmaceuticals, Inc.<br />
Novartis AG<br />
Cephalon, Inc.<br />
Eisai Co., Ltd.<br />
Genta Incorporated<br />
Sunesis Pharmaceuticals, Inc.<br />
SuperGen, Inc.<br />
Exelixis, Inc.<br />
Astex Therapeutics Limited<br />
Cyclacel Pharmaceuticals Inc.<br />
Vion Pharmaceuticals, Inc.<br />
Celgene Corporation<br />
Geron Corporation<br />
Merck KGaA<br />
Access Pharmaceuticals, Inc.<br />
EntreMed, Inc.<br />
EpiCept Corporation<br />
Ariad Pharmaceuticals, Inc.<br />
Lorus Therapeutics Inc<br />
MethylGene Inc<br />
Callisto Pharmaceuticals, Inc.<br />
ChemGenex Pharmaceuticals Limited<br />
OXiGENE, Inc.<br />
Critical Outcome Technologies Inc.<br />
CSL Limited<br />
TopoTarget A/S<br />
CytRx Corporation<br />
Pharmacyclics, Inc.<br />
Lipoxen PLC<br />
Threshold Pharmaceuticals, Inc.<br />
Synta Pharmaceuticals Corp.<br />
Sareum Holdings plc<br />
Clavis Pharma ASA<br />
Innate Pharma SA<br />
Baylor College of Medicine
Debiopharm Group<br />
Chroma Therapeutics Ltd.<br />
Avaris<br />
Actinium Pharmaceuticals, Inc.<br />
BioMAS Ltd.<br />
Calistoga Pharmaceuticals, Inc.<br />
Aegera Therapeutics Inc.<br />
Celator Pharmaceuticals, Inc.<br />
Altor BioScience Corporation<br />
Coronado Biosciences, Inc.<br />
Eleos Inc.<br />
Arno Therapeutics, Inc.<br />
S-BIO Pte Ltd<br />
Stemline Therapeutics, Inc.<br />
Proacta, Inc.<br />
Onconova Therapeutics, Inc<br />
Gemin X Pharmaceuticals<br />
Esperance Pharmaceuticals, Inc.<br />
Quatrx Pharmaceutical Company<br />
KaloBios Pharmaceuticals, Inc.<br />
Cylene Pharmaceuticals, Inc.<br />
SymbioTec GmbH<br />
AstraZeneca AB<br />
Kanisa Pharmaceuticals, Inc.<br />
Targa Therapeutics Corp.<br />
Sentinel Oncology Limited<br />
The Vaccine Company L.P.<br />
Universities/Institutes Involved in Acute Myelocytic Leukemia (AML) Therapeutics Development<br />
Acute Myelocytic Leukemia (AML) - Therapeutics Assessment<br />
Assessment by Monotherapy Products<br />
Assessment by Combination Products<br />
Assessment by Route of Administration<br />
Assessment by Molecule Type<br />
Late Stage Drug Profiles – Companies<br />
Aldesleukin + Maxamine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Aracytine + Daunorubicin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
AZACITIDINE (VIDAZA) - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
CEP-701 - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Ceplene - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Clolar + Cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
CYTARABINE - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine - Drug Profile
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Etoposide + Mitoxantrone + Lintuzumab - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Dacogen - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Daunorubicin + Cytarabine + Mylotarg - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
ELACYT - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
GM-CSF - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
GVAX Immunotherapy - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Mylotarg + Daunorubicin + Cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
PR1 Leukemia Peptide Vaccine + Incomplete Freund's Adjuvant + GM-CSF - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
PR1 Leukemia Peptide Vaccine + Sargramostim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Proleukin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Treosulfan + Busulfan - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Treosulfan + Fludarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Trisenox + Cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Vesanoid (ATRA) - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress
Vesanoid (ATRA) + AZACITIDINE (VIDAZA) - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Vesanoid(ATRA) + CYTARABINE - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Vidaza - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Vosaroxin + Cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Late Stage Drug Profiles – Universities/Institutes<br />
5-Azacytidin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Aldesleukin + Filgrastim + Asparaginase + Busulfan + Cyclophosphamide + Cytarabine +<br />
Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Fludarabine Phosphate + Idarubicin<br />
+ Methotrexate + Therapeutic Hydrocortisone + Thioguanine + Allogeneic Bone Marrow<br />
Transplantation + Radiation Therapy - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Aldesleukin + Filgrastim + Busulfan + Cyclophosphamide + Cytarabine + Daunorubicin<br />
Hydrochloride + Etoposide + Autologous Bone Marrow Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Aldesleukin + Filgrastim + Cyclophosphamide + Cytarabine + Etoposide + Idarubicin + Melphalan<br />
+ Peripheral blood stem cell transplantation + Radiation therapy - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
alemtuzumab + arsenic trioxide + azacitidine + busulfan + clofarabine + cytarabine + daunorubicin<br />
hydrochloride + fludarabine phosphate + gemtuzumab ozogamicin + melphalan + tipifarnib - Drug<br />
Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
all-trans retinoid acid + idarubicin + mitoxantrone + daunorubicin + cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
amsacrine + asparaginase + cytarabine + daunorubicin hydrochloride + etoposide + methotrexate<br />
+ mitoxantrone hydrochloride + therapeutic hydrocortisone + allogeneic bone marrow<br />
transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Amsacrine + Carmustine + Cytarabine + Etoposide + Idarubicin + Mitoxantrone Hydrochloride +<br />
Peripheral Blood Stem Cell Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Anthracyclines + liposomal daunorubicin + 2-CDA + AI - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress
Anti-thymocyte globulin + Cyclophosphamide + Cytarabine + Methylprednisolone + Thiotepa -<br />
Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Asparaginase + Cytarabine + Daunorubicin + Etoposide + Thioguanine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Asparaginase + Cytarabine + Daunorubicin Hydrochloride + Etoposide + Gemtuzumab Ozogamicin<br />
+ Mitoxantrone Hydrochloride - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
ATRA - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Busulfan + Cyclophosphamide + Autologous Stem Cell Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Busulfan + Cyclophosphamide + Melphalan + Allogeneic Hematopoietic Cell Transplantation - Drug<br />
Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Busulfan + Fludarabine + Cyclophosphamide + Radiation Therapy + Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Busulfan + Radiation Therapy + Peripheral Stem Cell Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Campath - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cerubidine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cladribine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cladribine + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
clofarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cyclophosphamide + Cyclosporine + Methotrexate + Stem Cell Transplantation + Radiation<br />
Therapy - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action
R&D Progress<br />
Cyclosporin + Methylprednisolone + Umbilical Cord Blood Stem Cell Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
cytarabine + daunorubicin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin + Etoposide - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin + Etoposide + Filgrastim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
cytarabine + daunorubicin + etoposide + hydroxyurea + idarubicin + mitoxantrone + thioguanine<br />
+ tretinoin + valspodar - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin + Gemtuzumab - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin + Mylotarg + Filgrastim/Sargramostim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin + Stem Cell Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin + Zosuquidar Trihydrochloride - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
cytarabine + daunorubicin hydrochloride + dexamethasone + etoposide + idarubicin +<br />
mitoxantrone hydrochloride + thioguanine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Daunorubicin hydrochloride + Etoposide - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
cytarabine + daunorubicin hydrochloride + midostaurin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress
cytarabine + etoposide + idarubicin + mitoxantrone - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Etoposide + Idarubicin + Mitoxantrone Hydrochloride + Gemtuzumab Ozogamicin -<br />
Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Gemtuzumab Ozogamicin + Sargramostim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Idarubicin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Idarubicin + All-trans retinoic acid + Mitoxantrone + Etoposid - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Idarubicin + Etoposide + All-trans retinoic acid + Pegfilgrastim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Idarubicin + Etoposide + ATRA + Pegfilgrastim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Idarubicin + Etoposide + Pegfilgrastim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Idarubicin + Mitoxantrone + All-trans-Retinoic Acid + Etoposide - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Thioguanine + Daunorubicin + Cyclophosphamide + G-CSF - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine + Thioguanine + Daunorubicin + Cyclophosphamide + G-CSF + stem cell<br />
transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine+ Idarubicin +Etoposide+ All-trans retinoic acid+ Pegfilgrastim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine+ Idarubicin +Etoposide+ Fludarabine +G-CSF - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytarabine+ Idarubicin All-trans retinoic acid+ Mitoxantrone+ Etoposide - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
cytosine arabinoside - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Cytosine Arabinoside + Idarubicin + Etoposide + Stem Cell Transplantation - Drug Profile
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Daunorubicin + Chemotherapy - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Daunorubicin + Cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Daunorubicin + Cytarabine + Etoposide + Cyclophosphamide + Busulfan + Interleukin-2 + PBSCT -<br />
Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Daunorubicin + Cytarabine + Midostaurin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
DAUNORUBICINE + CYTARABINE - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
DaunoXome - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Daunoxome - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
decitabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Enocitabine + Daunorubicin + Mercaptopurine + Mitoxantrone + Etoposide + Vindesine +<br />
Aclarubicin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Filgrastim + Amsacrine + Carmustine + Cytarabine + Etoposide + Idarubicin + Mitoxantrone<br />
Hydrochloride + Peripheral Blood Stem Cell Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
filgrastim + amsacrine + cyclophosphamide + cytarabine + daunorubicin hydrochloride + etoposide<br />
+ idarubicin + mitoxantrone hydrochloride + thioguanine + tretinoin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
filgrastim + amsacrine + cyclophosphamide + cytarabine + daunorubicin hydrochloride + etoposide<br />
+ idarubicin + mitoxantrone hydrochloride + thioguanine + tretinoin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Filgrastim + Busulfan + Cyclophosphamide + Cytarabine + Daunorubicin hydrochloride + Etoposide<br />
+ Idarubicin + Mesna + Mitoxantrone hydrochloride + Stem cell transplantation + Radiation<br />
therapy - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
filgrastim + cytarabine + daunorubicin hydrochloride + etoposide + fludarabine phosphate +
tretinoin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
filgrastim + cytarabine + daunorubicin hydrochloride + etoposide + fludarabine phosphate +<br />
tretinoin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Filgrastim + Sargramostim + Busulfan + Cyclophosphamide + Gemtuzumab Ozogamicin - Drug<br />
Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Filgrastim + Sargramostim + Cytarabine + Daunorubicin Hydrochloride + Gemtuzumab ozogamicin<br />
- Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Filgrastim + Sargramostim + Cytarabine + Daunorubicin Hydrochloride + Gemtuzumab ozogamicin<br />
- Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Fludarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Fludarabine + Busulfan + Campath-1H - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Fludarabine + Cytarabine + DaunoXome + Etoposide + Thioguanine + Cyclophosphamide +<br />
Busulfan + Melphalan - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Fludarabine + Cytarabine + Filgrastim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Fludarabine + Cytarabine + Idarubicin + Mylotarg - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
G-CSF - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Gemtuzumab ozogamicin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Gemtuzumab Ozogamicin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Hematopoietic Cell Transplantation + Total Body Irradiation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Idarubicin + Chemotherapy - Drug Profile<br />
Product Description
Mechanism of Action<br />
R&D Progress<br />
Idarubicin + Cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Idarubicin + Cytarabine + Daunorubicin hydrochloride + Dexamethasone + Etoposide +<br />
Thioguanine + Radiation therapy - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Idarubicin + Cytarabine + Lomustine + Methotrexate + 6-Mercaptopurine + Noreth<strong>and</strong>rolone -<br />
Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Idarubicin + Cytarabine + Thioguanine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Idarubicin + Etoposide - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
liposomal daunorubicin + fludarabine + ara-C + G-CSF - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Lomustine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Mercaptopurine + Methotrexate + Tretinoin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Mitoxantrone hydrochloride + Cytarabine + Daunorubicin hydrochloride + Dexamethasone +<br />
Etoposide + Thioguanine + Radiation therapy - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Mitoxantrone Hydrochloride + Etoposide + Cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Mylotarg - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Mylotarg + Daunorubicin + Cytarabine + Mitoxantrone + Stem Cell Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Mylotarg + Idarubicin + Etoposide + Cytarabine + ATRA + Pegfilgrastim - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
oblimersen sodium + cytarabine + daunorubicin hydrochloride - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Procrit - Drug Profile<br />
Product Description
Mechanism of Action<br />
R&D Progress<br />
PSC-833 + Cytarabine + Daunorubicin hydrochloride + Etoposide - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Recombinant flt3 lig<strong>and</strong> - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Thiotepa + Cyclophosphamide + ATG + OKT3 + Rituximab + Radiation therapy + Stem cell<br />
tranplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Thymoglobulin for Cancer - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Tipifarnib - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Tretinoin + Cytarabine + Daunorubicin + Arsenic Trioxide + Mercaptopurine + Methotrexate - Drug<br />
Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Tretinoin + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Tretinoin + Idarubicin + Mitoxantrone Hydrochloride + Mercaptopurine + Methotrexate - Drug<br />
Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Tretinoin + Idraubicin + cytarabine + Mitoxantrone + Etoposide + Allogenic Bone Marrow<br />
Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Trisenox + Cytarabine + Idarubicin + Mercaptopurine + Methotrexate + Mitoxantrone<br />
hydrochloride + Tretinoin - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Umbilical Cord Blood Transplantation - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Vidaza - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Vidaza - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress<br />
Zosuquidar Trihydrochloride + Daunorubicin + Cytarabine - Drug Profile<br />
Product Description<br />
Mechanism of Action<br />
R&D Progress
Discontinued Products<br />
Acute Myelocytic Leukemia (AML) - Featured News<br />
1. Dec 21, 2010: EpiCept Wins Israeli Approval For Ceplene<br />
2. Dec 21, 2010: Sunesis Begins Phase III Trial Of Vosaroxin In Acute Myeloid Leukemia<br />
3. Dec 07, 2010: Celator Reports Positive Phase II Study Data On CPX-351 In Acute Myeloid<br />
Leukemia<br />
4. Dec 07, 2010: Celgene Announces Study Results Of REVLIMID On Risk Of Progression To Acute<br />
Myeloid Leukaemia In Patients With Myelodysplastic Syndromes<br />
5. Dec 06, 2010: Ascenta And Leukemia & Lymphoma Society Sign Agreement To Develop AT-406<br />
6. Dec 06, 2010: Geron Presents Clinical Data On Telomerase Vaccine At 2010 American Society Of<br />
Hematology Meeting<br />
7. Dec 06, 2010: Millennium Reports Encouraging Phase I Results Of MLN4924 In Acute Myeloid<br />
Leukemia<br />
8. Dec 05, 2010: EpiCept Announces Ceplene Poster Presentation At Annual Meeting of American<br />
Society Of Hematology<br />
9. Dec 03, 2010: Lig<strong>and</strong> Announces Presentation Of Data From Multiple Studies Of Dinaciclib By<br />
Merck At ASH Annual Meeting<br />
10. Dec 03, 2010: SuperGen To Present SGI-110 Preclinical Data At ASH Annual Meeting<br />
Appendix<br />
Methodology<br />
Coverage<br />
Secondary <strong>Research</strong><br />
Primary <strong>Research</strong><br />
Expert Panel Validation<br />
Contact Us<br />
Disclaimer<br />
List of Tables<br />
Number of Products Under Development for Acute Myelocytic Leukemia (AML), 2011<br />
Products under Development for Acute Myelocytic Leukemia (AML) – Comparative Analysis, 2011<br />
Comparative Analysis by Late Stage Development, 2011<br />
Comparative Analysis by Mid Clinical Stage Development, 2011<br />
Comparative Analysis by Early Clinical Stage Development, 2011<br />
Comparative Analysis by Discovery <strong>and</strong> Pre-Clinical Stage Development, 2011<br />
Bristol-Myers Squibb Company, 2011<br />
Genzyme Corporation, 2011<br />
Johnson & Johnson, 2011<br />
Boehringer Ingelheim GmbH, 2011<br />
F. Hoffmann-La Roche Ltd., 2011<br />
Sanofi-Aventis, 2011<br />
AstraZeneca PLC, 2011<br />
Eli Lilly <strong>and</strong> Company, 2011<br />
Seattle Genetics, Inc., 2011<br />
medac GmbH, 2011<br />
Merck & Co., Inc., 2011<br />
Micromet, Inc., 2011<br />
Generex Biotechnology Corporation, 2011<br />
Takeda Pharmaceutical Company Limited, 2011<br />
Bio-Path Holdings, Inc., 2011<br />
BioSante Pharmaceuticals, Inc., 2011<br />
Novartis AG, 2011<br />
Cephalon, Inc., 2011<br />
Eisai Co., Ltd., 2011<br />
Genta Incorporated, 2011<br />
Sunesis Pharmaceuticals, Inc., 2011<br />
SuperGen, Inc., 2011<br />
Exelixis, Inc., 2011<br />
Astex Therapeutics Limited, 2011<br />
Cyclacel Pharmaceuticals Inc., 2011<br />
Vion Pharmaceuticals, Inc., 2011<br />
Celgene Corporation, 2011<br />
Geron Corporation, 2011<br />
Merck KGaA, 2011
Access Pharmaceuticals, Inc., 2011<br />
EntreMed, Inc., 2011<br />
EpiCept Corporation, 2011<br />
Ariad Pharmaceuticals, Inc., 2011<br />
Lorus Therapeutics Inc, 2011<br />
MethylGene Inc, 2011<br />
Callisto Pharmaceuticals, Inc., 2011<br />
ChemGenex Pharmaceuticals Limited, 2011<br />
OXiGENE, Inc., 2011<br />
Critical Outcome Technologies Inc., 2011<br />
CSL Limited, 2011<br />
TopoTarget A/S, 2011<br />
CytRx Corporation, 2011<br />
Pharmacyclics, Inc., 2011<br />
Lipoxen PLC, 2011<br />
Threshold Pharmaceuticals, Inc., 2011<br />
Synta Pharmaceuticals Corp., 2011<br />
Sareum Holdings plc, 2011<br />
Clavis Pharma ASA, 2011<br />
Innate Pharma SA, 2011<br />
Baylor College of Medicine, 2011<br />
Debiopharm Group, 2011<br />
Chroma Therapeutics Ltd., 2011<br />
Avaris, 2011<br />
Actinium Pharmaceuticals, Inc., 2011<br />
BioMAS Ltd., 2011<br />
Calistoga Pharmaceuticals, Inc., 2011<br />
Aegera Therapeutics Inc., 2011<br />
Celator Pharmaceuticals, Inc., 2011<br />
Altor BioScience Corporation, 2011<br />
Coronado Biosciences, Inc., 2011<br />
Eleos Inc., 2011<br />
Arno Therapeutics, Inc., 2011<br />
S-BIO Pte Ltd, 2011<br />
Stemline Therapeutics, Inc., 2011<br />
Proacta, Inc., 2011<br />
Onconova Therapeutics, Inc, 2011<br />
Gemin X Pharmaceuticals, 2011<br />
Esperance Pharmaceuticals, Inc., 2011<br />
Quatrx Pharmaceutical Company, 2011<br />
KaloBios Pharmaceuticals, Inc., 2011<br />
Cylene Pharmaceuticals, Inc., 2011<br />
SymbioTec GmbH, 2011<br />
AstraZeneca AB, 2011<br />
Kanisa Pharmaceuticals, Inc., 2011<br />
Targa Therapeutics Corp., 2011<br />
Sentinel Oncology Limited, 2011<br />
The Vaccine Company L.P., 2011<br />
Assessment by Monotherapy Products, 2011<br />
Assessment by Combination Products<br />
Assessment by Stage <strong>and</strong> Route of Administration, 2011<br />
Assessment by Molecule Type, 2011<br />
Discontinued Products<br />
List of Figures<br />
Number of Products under Development for Acute Myelocytic Leukemia (AML), 2011<br />
Products under Development for Acute Myelocytic Leukemia (AML) – Comparative Analysis, 2011<br />
Products under Development by Companies, 2011<br />
Products under Investigation by Universities/Institutes, 2011<br />
Late Stage Products, 2011<br />
Mid Clinical Stage Products, 2011<br />
Early Clinical Stage Products, 2011<br />
Discovery <strong>and</strong> Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011<br />
Assessment by Combination Products, 2011<br />
Assessment by Route of Administration, 2011<br />
Assessment by Stage <strong>and</strong> Route of Administration, 2011<br />
Assessment by Molecule Type, 2011<br />
Assessment by Stage <strong>and</strong> Molecule Type, 2011<br />
Ordering: Order Online - http://www.research<strong>and</strong>markets.com/reports/1574035/<br />
Order by Fax - using the form below<br />
Order by Post - print the order form below <strong>and</strong> send to<br />
<strong>Research</strong> <strong>and</strong> <strong>Markets</strong>,<br />
Guinness Centre,<br />
Taylors Lane,<br />
Dublin 8,<br />
Irel<strong>and</strong>.
Page 1 of 2<br />
Fax Order Form<br />
To place an order via fax simply print this form, fill in the information below <strong>and</strong> fax the completed form to 646-607-<br />
1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit<br />
http://www.research<strong>and</strong>markets.com/contact/<br />
Order Information<br />
Please verify that the product information is correct <strong>and</strong> select the format(s) you require.<br />
Product Formats<br />
Please select the product formats <strong>and</strong> quantity you require:<br />
Contact Information<br />
Product Name: Acute Myelocytic Leukemia (AML) - Pipeline Review, Q1 2011<br />
Web Address: http://www.research<strong>and</strong>markets.com/reports/1574035/<br />
Office Code: OC8DJIQTSRVRPQ<br />
Electronic -<br />
Single User:<br />
Electronic -<br />
Enterprisewide:<br />
Electronic - Site<br />
License:<br />
Quantity<br />
EURO€ 391.00<br />
EURO€ 1,174.00<br />
EURO€ 783.00<br />
Please enter all the information below in BLOCK CAPITALS<br />
Title: Mr<br />
First Name:<br />
Email Address: *<br />
Job Title:<br />
Organisation:<br />
Address:<br />
City:<br />
Postal / Zip Code:<br />
Country:<br />
Phone Number:<br />
Fax Number:<br />
Mrs Dr<br />
Miss Ms<br />
Last Name:<br />
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)<br />
Prof
Payment Information<br />
Page 2 of 2<br />
Please indicate the payment method you would like to use by selecting the appropriate box.<br />
Pay by credit card: American Express<br />
Diners Club<br />
Master Card<br />
Visa<br />
Cardholder's Name<br />
Cardholder's Signature<br />
Expiry Date<br />
Card Number<br />
CVV Number<br />
Issue Date<br />
(for Diners Club only)<br />
Pay by check: Please post the check, accompanied by this form, to:<br />
Pay by wire transfer:<br />
<strong>Research</strong> <strong>and</strong> <strong>Markets</strong>,<br />
Guinness Center,<br />
Taylors Lane,<br />
Dublin 8,<br />
Irel<strong>and</strong>.<br />
Please transfer funds to:<br />
If you have a Marketing Code please enter it below:<br />
Marketing Code:<br />
Account number 833 130 83<br />
Sort code 98-53-30<br />
Swift code ULSBIE2D<br />
IBAN number IE78ULSB98533083313083<br />
Bank Address Ulster Bank,<br />
27-35 Main Street,<br />
Blackrock,<br />
Co. Dublin,<br />
Irel<strong>and</strong>.<br />
Please note that by ordering from <strong>Research</strong> <strong>and</strong> <strong>Markets</strong> you are agreeing to our Terms <strong>and</strong> Conditions at<br />
http://www.research<strong>and</strong>markets.com/info/terms.asp<br />
Please fax this form to:<br />
(646) 607-1907 or (646) 964-6609 - From USA<br />
+353-1-481-1716 or +353-1-653-1571 - From Rest of World
Change language